On the authoritative american magazineNature Communications” were published the data of a research coordinated by the IRCCS-Istituto di Ricerche Farmacologiche ‘Mario Negri’, and demonstrates the responsibilityà of an RNA molecule, called mir-181a, in the proliferation of tumor metastasis to the ovary, and in the resistance to anticancer drugs.
The Unità Genomics Translational, directed by Sergio Marchini Department of Oncology, directed by Maurizio D’incalci at the Mario Negri Institute of Milan, through a grant from AIRC, has identified a small RNA molecule, called mir-181a, which seems to be extremely important in the drive mechanisms of resistance to therapy.
Through a fruitful collaboration with a group of american researchers, led by Analisa Di Feo of the “Case Comprehensive Cancer Center” of Cleveland, and with the group of bioinformatics of the Università di Padova, directed by Chiara Romualdi, researchers at the Mario Negri have shown that in two different series of patients, an Italian of the San Gerardo Hospital of Monza and an american one from the Mount Sinai of New York, the expression of mir-181a correlated inversely with the survival of patients.
“The patients that expressed più – says Sergio Marchini, Head of the Unità Genomics Translational Institute Mario Negri, recidivavano più early and their illness was resistant to treatment and progressing più quickly. It is observed in mice transplanted with human tumors of the ovary by increasing the expression of mir-181a cells of carcinoma of the ovary become much more mobile, they form a number of metastases greater and become insensitive to pharmacological therapies. By blocking this molecule reversed many of the characteristics of malignità and the resistance of tumor cells”.
“ovarian cancer”, concludes Maurizio D’incalci Department of Oncology Mario Negri Institute – not è a single disease but many different diseases that differ for the extension, pathologic characteristics, sensitivityà to treatment to survival. The search results open up new prospects to characterize so più precise the patients with carcinoma of the ovary and to identify new therapies.”
The Mario Negri Institute of Milan for many years to understand the reasons at the basis of a variable course of the illness and the different sensitivityà the treatment of patients with carcinoma of the ovary, conducting biological studies, very extensive use of technological platforms that allow the simultaneous evaluation of several thousands of genes.
Prevention of cancer
A Pap Test for the diagnosis of cancer of the ovary and of the uterus
polycystic Ovarian syndrome: what is it, symptoms, causes, diagnosis, and treatment
ovarian Cysts: causes, symptoms, diagnosis, and treatment
8 January 2014